Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Multiple Sclerosis News

News
Novel Method Measures Whole-Brain Propagation Delays in Patients with MS
11/29/2022
A new approach described in the Journal of Neuroscience calculates functional delays across the whole brain of patients with multiple sclerosis (MS), providing a more precise measure of myelinic damage that can help guide treatment.
A new approach described in the Journal of Neuroscience calculates functional delays across the whole brain of patients with multiple sclerosis (MS), providing a more precise measure of myelinic damage that can help guide treatment.
A new approach described in the...
11/29/2022
Neurology
News
Study Tracks Immune Cell Regeneration After Stem Cell Therapy for MS
11/21/2022
Memory T cells reappear immediately after blood stem cell transplantation in patients with multiple sclerosis (MS), according to a study published in Science Translational Medicine.
Memory T cells reappear immediately after blood stem cell transplantation in patients with multiple sclerosis (MS), according to a study published in Science Translational Medicine.
Memory T cells reappear...
11/21/2022
Neurology
News
Ocrelizumab Concentration May Aid in SARS-CoV-2 Vaccine Timing for Patients With MS
11/08/2022
Serum ocrelizumab concentration measured at the time of vaccination predicted humoral response after SARS-CoV-2 vaccination in patients with multiple sclerosis (MS), with an accuracy comparable to B-cell count.
Serum ocrelizumab concentration measured at the time of vaccination predicted humoral response after SARS-CoV-2 vaccination in patients with multiple sclerosis (MS), with an accuracy comparable to B-cell count.
Serum ocrelizumab concentration...
11/08/2022
Neurology

Advertisement

News
Disease-Modifying Treatments for Primary Progressive MS May Lower Risk of Wheelchair Dependence
09/12/2022
Disease-modifying treatments in patients with primary progressive multiple sclerosis (MS) and persistent inflammatory activity may lower the risk of becoming wheelchair dependent, according to study findings published online in JAMA Neurology.
Disease-modifying treatments in patients with primary progressive multiple sclerosis (MS) and persistent inflammatory activity may lower the risk of becoming wheelchair dependent, according to study findings published online in JAMA Neurology.
Disease-modifying treatments in...
09/12/2022
Neurology
News
Ketogenic Diet Shows Benefit for Patients With Multiple Sclerosis
05/31/2022
Adherence to a 6-month ketogenic diet reduced fatigue and depression scores by almost half in patients with multiple sclerosis (MS), according to results from a phase 2 study published in the Journal of Neurology, Neurosurgery & Psychiatry.
Adherence to a 6-month ketogenic diet reduced fatigue and depression scores by almost half in patients with multiple sclerosis (MS), according to results from a phase 2 study published in the Journal of Neurology, Neurosurgery & Psychiatry.
Adherence to a 6-month ketogenic...
05/31/2022
Neurology
News
Smoking, Alcohol Recommendations Particularly Relevant for Those With MS
05/06/2022
Smoking was associated with increased odds of being diagnosed with multiple sclerosis (MS), and high alcohol consumption was associated with more pronounced retinal features of neurodegeneration in people with MS.
Smoking was associated with increased odds of being diagnosed with multiple sclerosis (MS), and high alcohol consumption was associated with more pronounced retinal features of neurodegeneration in people with MS.
Smoking was associated with...
05/06/2022
Neurology

Advertisement

News
Dairy Products May Aggravate MS Symptoms in Patients With Casein Intolerance
04/13/2022
Study results show consuming cow’s milk may aggravate multiple sclerosis (MS) symptoms in a subset of patients with an intolerance to bovine casein.
Study results show consuming cow’s milk may aggravate multiple sclerosis (MS) symptoms in a subset of patients with an intolerance to bovine casein.
Study results show consuming...
04/13/2022
Neurology
News
Anti-CD20 Monoclonal Antibody Shows Favorable Benefit for Relapsing Multiple Sclerosis
03/31/2022
The first fully human anti-CD20 monoclonal antibody, ofatumumab, provided a favorable benefit-risk profile in patients with relapsing multiple sclerosis.
The first fully human anti-CD20 monoclonal antibody, ofatumumab, provided a favorable benefit-risk profile in patients with relapsing multiple sclerosis.
The first fully human anti-CD20...
03/31/2022
Neurology
News
Serum Neurofilament Light Chain in Determining Multiple Sclerosis Disease Activity
02/25/2022
Serum neurofilament light chain (sNfL) percentiles in addition to Z scores can help identify patients with multiple sclerosis (MS) who are at risk for detrimental disease courses.
Serum neurofilament light chain (sNfL) percentiles in addition to Z scores can help identify patients with multiple sclerosis (MS) who are at risk for detrimental disease courses.
Serum neurofilament light chain...
02/25/2022
Neurology

Advertisement

News
Internet-Delivered Mindfulness-Based Intervention Beneficial for Patients With MS and Depression
02/25/2022
For patients with multiple sclerosis (MS), internet-delivered mindfulness-based intervention (MBI) can improve symptoms of depression, according to recent study findings.
For patients with multiple sclerosis (MS), internet-delivered mindfulness-based intervention (MBI) can improve symptoms of depression, according to recent study findings.
For patients with multiple...
02/25/2022
Neurology

Advertisement

Advertisement

News

Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
News
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
08/08/2024
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive...
08/08/2024
Neurology
brain waves
News
High-Dose Statins May Not Benefit Patients With Mild Ischemic Stroke
08/08/2024
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose...
08/08/2024
Neurology
An illustration of a healthcare provider conducting a telehealth appointment
News
Teleneurology Visits Acceptable to Patients Across Neurologic Conditions
08/05/2024
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic...
08/05/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
DMD Gene Therapy Indication Expanded to Include Boys 4 and Older
08/01/2024
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an...
08/01/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS
07/30/2024
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve,...
07/30/2024
Neurology
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
News
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
07/29/2024
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod...
07/29/2024
Neurology
A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
News
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
07/23/2024
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug...
07/23/2024
Neurology
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
News
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
07/22/2024
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was...
07/22/2024
Neurology
a hand breaks a wooden human figurine in half
News
Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse
07/18/2024
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related...
07/18/2024
Neurology

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use